SG11201408810TA - Methods of treating arthritis - Google Patents
Methods of treating arthritisInfo
- Publication number
- SG11201408810TA SG11201408810TA SG11201408810TA SG11201408810TA SG11201408810TA SG 11201408810T A SG11201408810T A SG 11201408810TA SG 11201408810T A SG11201408810T A SG 11201408810TA SG 11201408810T A SG11201408810T A SG 11201408810TA SG 11201408810T A SG11201408810T A SG 11201408810TA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- taipei city
- san francisco
- street
- south san
- Prior art date
Links
- 206010003246 arthritis Diseases 0.000 title abstract 2
- 229960000074 biopharmaceutical Drugs 0.000 abstract 1
- 239000002502 liposome Substances 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Dispersion Chemistry (AREA)
- Immunology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Rheumatology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Pain & Pain Management (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261668446P | 2012-07-05 | 2012-07-05 | |
| US201361791650P | 2013-03-15 | 2013-03-15 | |
| PCT/US2013/049442 WO2014008469A2 (fr) | 2012-07-05 | 2013-07-05 | Méthodes de traitement de l'arthrite |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201408810TA true SG11201408810TA (en) | 2015-01-29 |
Family
ID=49882628
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201408810TA SG11201408810TA (en) | 2012-07-05 | 2013-07-05 | Methods of treating arthritis |
| SG10201610887WA SG10201610887WA (en) | 2012-07-05 | 2013-07-05 | Methods of treating arthritis |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201610887WA SG10201610887WA (en) | 2012-07-05 | 2013-07-05 | Methods of treating arthritis |
Country Status (25)
| Country | Link |
|---|---|
| US (5) | US9789062B2 (fr) |
| EP (1) | EP2854769B1 (fr) |
| JP (2) | JP6535281B2 (fr) |
| KR (2) | KR102302503B1 (fr) |
| CN (1) | CN105377238B (fr) |
| AU (1) | AU2013286575B2 (fr) |
| BR (1) | BR112015000174A2 (fr) |
| CA (1) | CA2878152C (fr) |
| CY (1) | CY1126136T1 (fr) |
| DK (1) | DK2854769T3 (fr) |
| ES (1) | ES2949093T3 (fr) |
| FI (1) | FI2854769T3 (fr) |
| HK (1) | HK1219414A1 (fr) |
| HR (1) | HRP20230655T1 (fr) |
| HU (1) | HUE062466T2 (fr) |
| LT (1) | LT2854769T (fr) |
| NZ (1) | NZ703532A (fr) |
| PL (1) | PL2854769T3 (fr) |
| PT (1) | PT2854769T (fr) |
| RU (1) | RU2677658C2 (fr) |
| SG (2) | SG11201408810TA (fr) |
| SI (1) | SI2854769T1 (fr) |
| TW (1) | TWI556838B (fr) |
| WO (1) | WO2014008469A2 (fr) |
| ZA (1) | ZA201500152B (fr) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10610486B2 (en) * | 2010-10-28 | 2020-04-07 | Pacira Pharmaceuticals, Inc. | Sustained release formulation of a non-steroidal anti-inflammatory drug |
| WO2017203529A1 (fr) * | 2016-05-24 | 2017-11-30 | Bol Pharma Ltd. | Compositions comprenant du cannabidiol et de l'acide hyaluronique pour le traitement de maladies inflammatoires des articulations |
| WO2018019843A1 (fr) * | 2016-07-26 | 2018-02-01 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antagonistes du récepteur des minéralocorticoïdes pour le traitement de l'arthrose |
| CN107670020B (zh) * | 2016-08-02 | 2020-09-18 | 富比积生物科技股份有限公司 | 四胜肽gekg在治疗退化性关节炎中的用途 |
| WO2018094253A1 (fr) | 2016-11-18 | 2018-05-24 | Pacira Pharmaceuticals, Inc. | Formulations de liposomes multivésiculaires à microparticules de complexe de méloxicam de zinc et leurs procédés de fabrication |
| RU2667467C1 (ru) * | 2017-05-17 | 2018-09-19 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Национальный исследовательский Мордовский государственный университет им. Н.П. Огарёва" | Липосомальный препарат дексаметазона в гипертоническом растворе хлорида натрия и способ лечения острого повреждения легких на его основе |
| US20200230057A1 (en) * | 2017-07-10 | 2020-07-23 | Immunovaccine Technologies Inc. | Pharmaceutical Compositions, Methods for Preparation using Lipid Vesicle Particles of Defined Size, and Uses Thereof |
| NZ761298A (en) * | 2017-08-22 | 2024-03-22 | Moebius Medical Ltd | Liposomal formulation for joint lubrication |
| CN111565706A (zh) * | 2017-11-09 | 2020-08-21 | 免疫疫苗技术公司 | 药物组合物、包括脂质囊泡颗粒尺寸设定的制备方法及其用途 |
| US20210196733A1 (en) * | 2018-07-09 | 2021-07-01 | Taiwan Liposome Co., Ltd. | Methods to reduce complications of intra-articular steroid |
| WO2020056399A1 (fr) * | 2018-09-16 | 2020-03-19 | Tlc Biopharmaceuticals, Inc. | Compositions pharmaceutiques appropriées pour une administration articulaire et leur utilisation dans le traitement de la douleur articulaire |
| WO2020102323A1 (fr) * | 2018-11-14 | 2020-05-22 | Taiwan Liposome Co., Ltd. | Compositions pharmaceutiques à libération prolongée comprenant un agent thérapeutique pour le traitement de maladies dues à une densité osseuse réduite ou à une perte de cartilage et leurs utilisations |
| US11896713B2 (en) * | 2020-10-22 | 2024-02-13 | Rutgers, The State University Of New Jersey | Strategies to enhance lung cancer treatment |
| CN112791063A (zh) * | 2021-01-19 | 2021-05-14 | 南通市中医院 | 一种用于清除关节腔积液中炎症因子及释放抗炎药物的载体 |
| RU2762105C1 (ru) * | 2021-05-25 | 2021-12-15 | федеральное государственное бюджетное образовательное учреждение высшего образования "Башкирский государственный медицинский университет" Министерства здравоохранения Российской Федерации | Способ оценки эффективности лечения псориатического артрита с помощью параметров антиоксидантной системы |
| WO2023014972A2 (fr) * | 2021-08-06 | 2023-02-09 | New York R&D Center For Translational Medicine And Therapeutics, Inc. | Compositions de microarn et procédés d'utilisation |
| WO2023172594A2 (fr) * | 2022-03-08 | 2023-09-14 | Nova Southeastern University | Méthode de traitement de l'arthrite rhumatoïde (ra) à l'aide d'un inhibiteur d'exosite sélectifs d'enzyme et de substrat d'une désintégrine a et d'une métalloprotéase 10 (adam10) |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ201010A (en) * | 1981-06-19 | 1986-02-21 | Ciba Geigy Ag | The treatment of inflammation diseases using desferrioxamine |
| MX9203290A (es) * | 1983-09-19 | 1992-08-01 | Liposome Co Inc | Suministro localizado usando conjugados de fibronectina. |
| US6759057B1 (en) | 1986-06-12 | 2004-07-06 | The Liposome Company, Inc. | Methods and compositions using liposome-encapsulated non-steroidal anti-inflammatory drugs |
| US6270766B1 (en) * | 1992-10-08 | 2001-08-07 | The Kennedy Institute Of Rheumatology | Anti-TNF antibodies and methotrexate in the treatment of arthritis and crohn's disease |
| US5846217A (en) * | 1997-07-29 | 1998-12-08 | Iomed, Inc. | Iontophoretic bioelectrode and method of using same |
| US20050123593A1 (en) * | 2001-06-25 | 2005-06-09 | Jonathan Thompson | Liposomal encapsulation of glycosaminoglycans for the treatment of arthritic joints |
| GB0118517D0 (en) | 2001-07-30 | 2001-09-19 | Mitsubishi Tokyo Pharm Inc | Compound |
| EP1371362A1 (fr) * | 2002-06-12 | 2003-12-17 | Universiteit Utrecht Holding B.V. | Composition pour le traitement de troubles inflammatoires |
| BRPI0409652A (pt) * | 2003-04-24 | 2006-04-25 | Jagotec Ag | tablete, embalagem farmacêutica, método de tratamento de doenças, e, método de preparação de um tablete |
| WO2005097073A1 (fr) | 2004-03-31 | 2005-10-20 | University Of Utah Research Foundation | Systemes d'administration macromoleculaires destines a l'imagerie, a l'evaluation et au traitement non invasifs de l'arthrite et d'autres maladies inflammatoires |
| US20050260260A1 (en) * | 2004-05-19 | 2005-11-24 | Edward Kisak | Liposome compositions for the delivery of macromolecules |
| CA2579786A1 (fr) | 2004-09-09 | 2006-03-16 | Yissum Research Development Company Of The Hebrew University Of Jerusale M | Utilisation de glucocorticoides pour le traitement d'etats inflammatoires |
| EP1764091B1 (fr) | 2005-09-15 | 2017-08-30 | Marina Biotech, Inc. | Améliorations sur ou concernant des liposomes amphotères |
| ES2895078T3 (es) * | 2006-03-15 | 2022-02-17 | Brigham & Womens Hospital Inc | Uso de gelsolina para diagnosticar y tratar enfermedades inflamatorias |
| WO2007134819A1 (fr) | 2006-05-18 | 2007-11-29 | Medigene Ag | Préparations liposomales cationiques pour le traitement de la polyarthrite rhumatoïde |
| WO2008004556A1 (fr) | 2006-07-06 | 2008-01-10 | Sharp Kabushiki Kaisha | Module de cellule solaire sensible aux colorants et procédé de fabrication correspondant |
| WO2008030818A2 (fr) | 2006-09-05 | 2008-03-13 | Mebiopharm Co., Ltd. | Nouvelles compositions de liposomes |
| ES2400162T3 (es) * | 2006-10-06 | 2013-04-08 | Scil Technology Gmbh | Formación de vesículas reconstituidas y secadas para un uso farmacéutico |
| US8071127B2 (en) * | 2006-10-24 | 2011-12-06 | Aradigm Corporation | Dual action, inhaled formulations providing both an immediate and sustained release profile |
| US8956600B2 (en) * | 2009-08-10 | 2015-02-17 | Taiwan Liposome Co. Ltd. | Ophthalmic drug delivery system containing phospholipid and cholesterol |
| US9770414B2 (en) | 2010-05-13 | 2017-09-26 | Pacira Pharmaceuticals, Inc. | Sustained release formulation of methotrexate as a disease-modifying antirheumatic drug (DMARD) and an anti-cancer agent |
| US20130071321A1 (en) | 2010-05-28 | 2013-03-21 | Purdue Research Foundation | Delivery of agents to inflamed tissues using folate-targeted liposomes |
| US10610486B2 (en) | 2010-10-28 | 2020-04-07 | Pacira Pharmaceuticals, Inc. | Sustained release formulation of a non-steroidal anti-inflammatory drug |
-
2013
- 2013-07-05 SI SI201332050T patent/SI2854769T1/sl unknown
- 2013-07-05 SG SG11201408810TA patent/SG11201408810TA/en unknown
- 2013-07-05 FI FIEP13813286.5T patent/FI2854769T3/fi active
- 2013-07-05 TW TW102124244A patent/TWI556838B/zh active
- 2013-07-05 CA CA2878152A patent/CA2878152C/fr active Active
- 2013-07-05 RU RU2015103538A patent/RU2677658C2/ru active
- 2013-07-05 US US14/411,530 patent/US9789062B2/en active Active
- 2013-07-05 ES ES13813286T patent/ES2949093T3/es active Active
- 2013-07-05 KR KR1020207022150A patent/KR102302503B1/ko active IP Right Grant
- 2013-07-05 HU HUE13813286A patent/HUE062466T2/hu unknown
- 2013-07-05 DK DK13813286.5T patent/DK2854769T3/da active
- 2013-07-05 BR BR112015000174A patent/BR112015000174A2/pt not_active Application Discontinuation
- 2013-07-05 WO PCT/US2013/049442 patent/WO2014008469A2/fr active Application Filing
- 2013-07-05 KR KR1020157002869A patent/KR102176971B1/ko active IP Right Grant
- 2013-07-05 SG SG10201610887WA patent/SG10201610887WA/en unknown
- 2013-07-05 PL PL13813286.5T patent/PL2854769T3/pl unknown
- 2013-07-05 PT PT138132865T patent/PT2854769T/pt unknown
- 2013-07-05 CN CN201380035254.0A patent/CN105377238B/zh active Active
- 2013-07-05 EP EP13813286.5A patent/EP2854769B1/fr active Active
- 2013-07-05 HR HRP20230655TT patent/HRP20230655T1/hr unknown
- 2013-07-05 AU AU2013286575A patent/AU2013286575B2/en active Active
- 2013-07-05 JP JP2015520707A patent/JP6535281B2/ja active Active
- 2013-07-05 NZ NZ703532A patent/NZ703532A/en unknown
- 2013-07-05 LT LTEPPCT/US2013/049442T patent/LT2854769T/lt unknown
-
2015
- 2015-01-09 ZA ZA2015/00152A patent/ZA201500152B/en unknown
-
2016
- 2016-06-24 HK HK16107416.3A patent/HK1219414A1/zh unknown
-
2017
- 2017-09-05 US US15/695,649 patent/US10322086B2/en active Active
-
2018
- 2018-12-07 JP JP2018229873A patent/JP6964571B2/ja active Active
-
2019
- 2019-06-12 US US16/439,124 patent/US10736846B2/en active Active
-
2020
- 2020-05-15 US US16/875,167 patent/US10959951B2/en active Active
-
2021
- 2021-01-05 US US17/141,550 patent/US11793755B2/en active Active
-
2023
- 2023-07-10 CY CY20231100324T patent/CY1126136T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201408810TA (en) | Methods of treating arthritis | |
| SG11201805645QA (en) | Lsd1 inhibitors | |
| SG11201811564QA (en) | Methods of treating ovarian cancer | |
| SG11201808990QA (en) | Compositions for topical application of compounds | |
| SG11201500005SA (en) | Pyrimidine pyrazolyl derivatives | |
| SG11201906386XA (en) | Combination therapy involving diaryl macrocyclic compounds | |
| SG11201803920TA (en) | Compounds and compositions useful for treating disorders related to ntrk | |
| SG11201407200TA (en) | Liquid formulation | |
| SG11201808125RA (en) | Methods for solid tumor treatment | |
| SG11201408821SA (en) | Selective pi3k delta inhibitors | |
| SG11201805044WA (en) | Compounds useful as kinase inhibitors | |
| SG11201805570WA (en) | Systems and methods for long term transdermal administration | |
| SG11201810287RA (en) | Methods and compositions for treating non-erk mapk pathway inhibitor-resistant cancers | |
| SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
| SG11201903483VA (en) | Compositions and methods for treating ezh2-mediated cancer | |
| SG11201408750VA (en) | NOVEL FUSED PYRIDINE DERIVATIVES USEFUL AS c-MET TYROSINE KINASE INHIBITORS | |
| SG11201809024UA (en) | Cancer immunotherapy by immune activation or immune modulation via globo series antigens | |
| SG11201407898WA (en) | Electrode testing apparatus | |
| SG11201806251WA (en) | Methods for treating er+, her2-, hrg+ breast cancer using combination therapies comprising an anti-erbb3 antibody | |
| SG11201804360XA (en) | Mat2a inhibitors for treating mtap null cancer | |
| SG11201408163VA (en) | Modified fibronectin fragments or variants and uses thereof | |
| SG11201407372UA (en) | Nampt inhibitors | |
| SG11201407649RA (en) | Method for treating non-small cell lung cancer | |
| SG11201908602UA (en) | Combination therapy for the treatment of solid and hematological cancers | |
| SG11201805311XA (en) | Method of treating a mammal, including human, against cancer using methionine and asparagine depletion |